Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION
Go back to Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION| Management Of Environmental Solutions & Technology (NASDAQ: MESO) | Delayed: 15.44 -0.06 (0.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.50 | 52 Week High | $10.89 | |||
| Open | $15.05 | 52 Week Low | $3.50 | |||
| Day High | $15.46 | P/E | N/A | |||
| Day Low | $15.05 | EPS | $0.00 | |||
| Volume | 58,048 | |||||
| MESABI TRUST (NYSE: MSB) | Delayed: 24.35 -0.19 (0.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.54 | 52 Week High | $11.74 | |||
| Open | $24.16 | 52 Week Low | $3.00 | |||
| Day High | $25.08 | P/E | 15.41 | |||
| Day Low | $24.16 | EPS | $1.58 | |||
| Volume | 10,732 | |||||
